Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) are indicated as first-line therapy in patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations in the EGFR gene. Erlotinib is also used in second and third-line th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bisagni, Alessandra, Pagano, Maria, Maramotti, Sally, Zanelli, Francesca, Bonacini, Martina, Tagliavini, Elena, Braglia, Luca, Paci, Massimiliano, Mozzarelli, Andrea, Croci, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916492/
https://www.ncbi.nlm.nih.gov/pubmed/29689091
http://dx.doi.org/10.1371/journal.pone.0196350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916492/
https://www.ncbi.nlm.nih.gov/pubmed/29689091
http://dx.doi.org/10.1371/journal.pone.0196350

Ejemplares similares